

THIS STUDY NO LONGER RECRUITING

Name of Study: Riluzole Medication Study for Repetitive Behaviors or Obsessive-Compulsive Disorder (OCD)

Location: National Institute of Mental Health (NIMH), Bethesda, Maryland

Basic Eligibility Criteria:

- Children and adolescents, ages 7 through 17
- who are taking or have taken medication for repetitive behaviors or OCD

Principal Investigator: Paul Grant, M.D.

Contact Information: Lorraine Lougee, LCSW-C, Research Social Worker: 301-435-6652 or 301-496-5323 or OCDNIMH@intra.nimh.nih.gov.

Dear Parent,

We would like to inform you about an opportunity for you and your child to participate in a research study at the National Institute of Mental Health (NIMH) – part of the National Institutes of Health (NIH), Department of Health and Human Services, located in Bethesda, Maryland. The purpose of this study is to see if a medication called *riluzole* will be helpful to children and adolescents with repetitive behaviors or Obsessive-Compulsive Disorder (OCD).

Riluzole has already been approved by the U.S. Food and Drug Administration (FDA) for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's Disease).

Each participant will receive an initial comprehensive diagnostic assessment as well as a physical examination, medical history, and blood and urine tests, and a few other safe and painless procedures. This initial evaluation, after the screening visit, will take at least two days. Participants will be randomly chosen to receive either a riluzole or a placebo for 12 weeks. ("Placebo" means a pill with no active ingredients.) However, at the end of 12 weeks, all participants will have the option of taking open-label riluzole (that is, there will be no chance of receiving a placebo after that point).

After this phase of the research study, we will continue to collect information for one year. Most follow-up visits last about 2 ½ hours and are approximately once a month for the first 6 months, and then again at month 9, and once again at one year. These follow-up visits typically would *not* require an overnight stay unless the family comes from a great distance and finds it burdensome to travel to and from Bethesda in a single day.

There is no charge to participate in the study. Most travel expenses are covered. Parental consent is required.

THIS STUDY NO LONGER RECRUITING

If you are interested in participating, please contact Lorraine Lougee, our Research Social Worker, at 301-435-6652 or 301-496-5323. She will be happy to answer your questions and make arrangements for your participation.

Yours Truly,

Paul Grant, M.D.
Child and Adolescent Psychiatrist/Staff Clinician
National Institute of Mental Health (NIMH)
National Institutes of Health (NIH)
Bethesda, Maryland